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Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of diﬀerentiation of B-
lymphoid cells. Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far. The serum
concentration of sCD138 and some angiogenesis-involved cytokines: vascular endothelial growth factor (VEGF), basis ﬁbroblast
growth factor (bFGF), and endostatin were studied in 52 previously untreated patients with B-CLL. We found that bFGF and
sCD138 levels were signiﬁcantly higher in B-CLL patients than in controls. In patients with sCD138 level or endostatin level below
the median value the lymphocyte count was higher than in patients with serum level of those cytokines above the median value.
In patients with progressive disease bFGF level was signiﬁcantly higher and sCD138 level signiﬁcantly lower than in patients with
stable one. Moreover, high sCD138 level was associated with longer lymphocyte doubling-free survival, and, on the limit of statis-
tical signiﬁcance, a high endostatin level was associated with shorter progression-free survival. We conclude that serum sCD138
level is increased in early stage B-CLL patients and may have a positive prognostic value as to the dynamics of the disease.
Copyright © 2006 Dariusz Wołowiec et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Clinical picture of the B-cell chronic lymphocytic leukemia
(B-CLL) depends not only on the biological features of
leukemic lymphocytes but also on their environment, in par-
ticular on the serum level of diﬀerent cytokines. Some of
them are involved in the cell proliferation, maturation, and
survival, some other participate in the regulation of cell ad-
hesion and in the angiogenesis. In particular, tumor pro-
gression is profoundly inﬂuenced by cell-to-cell or cell-to-
matrix interactions mediated by transmembrane proteogly-
cans. Syndecans are members of a family of cell surface
transmembrane heparin sulfate proteoglycans which are in-
volved in the cell adhesion to the extracellular matrix act-
ing as receptor for such matrix elements as collagen, ﬁ-
bronectin, thrombospondin, and tenascin. They are also re-
ceptors for heparin-binding growth factors [1–3]. Syndecan-
1 (sCD138), although expressed mainly by epithelial cells,
seems also to play a role in the diﬀerentiation and survival of
theB lymphocytelineagecells.Inmiceitisdetectableonpre-
B cells,lostinmatureB cells,andreexpressedonplasmacells
[4]. In patients with multiple myeloma CD138 is expressed
on malignant plasma cells both in bone marrow and in pe-
ripheral blood and its ectodomain is shed from their surface
into culture medium in vitro and into the serum in vivo [5].
Inadditiontoitsroleincell-matrixadhesionandcell-cellad-
hesionbetweenmyelomacells,ithasbeenshownthatCD138
inﬂuences bone cell diﬀerentiation, promotes myeloma cell
apoptosis, and exerts an inhibitory eﬀect on their prolifera-
tion by downregulating cyclin D1 expression [6, 7]. Elevated
serum sCD138 level is an independent unfavorable prognos-
tic parameter in multiple myeloma [8]. However, up to now
much less is known about the expression and clinical role
of CD138 in other B-lineage-derived malignancies. In the
diﬀerence to the normal and malignant T cells, or CD5+
lymphocytes other than B-CLL lymphocytes, its expression
was found in B-CLL and lymphoplasmacytoid cells. It was
therefore proposed that CD138 expression might be used as
a phenotypic marker for this group of B-cell malignancies
[9, 10]. Despite this observation which indicates that CD138
may play a role in the pathogeny of B-CLL, no studies on
the serum level of sCD138 and its possible prognostic value2 Mediators of Inﬂammation
in B-CLL patients have been published so far. We evaluated
then the serum level of sCD138 in early B-CLL patients in
relationship to the disease aggressiveness. In addition, we
assessed the serum level of principal cytokines involved in
the angiogenesis, such as vascular endothelial growth factor
(VEGF), basic ﬁbroblast growth factor (bFGF), and endo-
statin.
PATIENTS
Fifty-twopreviouslyuntreatedpatients(30men,22women),
aged from 36 to 83 years (median 67), and 12 healthy age-
matchedvolunteerswereincludedtothestudy.Inallpatients
the diagnosis of B-CLL was established according to the Na-
tional Cancer Institute- (NCI-)Sponsored Working Group
diagnostic criteria for CLL [11]. According to Rai classiﬁca-
tion, 18 patients were in stage 0, whereas 26 were in stage
I, and remaining 8 were in stage II. An assessment of his-
tory and a physical examination was performed as initial di-
agnostic procedure. Each patient was described by following
diagnostic tests: complete blood count, liver and renal func-
tion tests, immunoglobulins, LDH, β2-microglobulin level,
bone marrow aspiration, immunophenotyping of peripheral
blood lymphocytes (PBLs) including CD38 positivity, chest
X-ray, and abdominal ultrasound. In 19 patients bone mar-
rowtrephinebiopsywasevaluablefortheassessmentofbone
marrow inﬁltration pattern.
Follow-up period ranged from 12 to 37 months (median
31). During this period the cytostatic treatment was started
in 23 patients because of the disease progression accord-
ing to the recommendations of the NCI-Sponsored Work-
ing Group diagnostic criteria for CLL [11]. In 16 patients
the indication was the rapid increase of PBL, that is, lym-
phocytosis doubling time (LDT) shorter than 1 year. In the
remaining 7 the treatment was administered because of the
appearance of other signs of progressive disease: thrombo-
cytopenia or the rapid increase of spleen or lymph nodes.
During the treatment-free period the appearance of higher
stage according to Rai classiﬁcation was stated in 5 patients.
The remaining 29 patients did not need treatment during
the whole follow-up period. The mean follow-up period was
similar forpatients whoreceivedcytostatic treatmentandfor
those who did not require therapy (29.2 and 29.6 months,
resp).
In44patientsPBLdidnotdoublewithinoneyearfollow-
ing the enrolment to the study. In 8 remaining patients LDT
was no longer than 12 months, and those patients started to
be treated for this reason. Two other patients had to undergo
the cytostatic treatment within 12 months after the enrol-
ment to the study for other indications than the rapid in-
crease of PBL.
Prognostic values of the initial cytokine concentrations
were assessed for patients with LDT no longer than 12
months versus those in whom the PBL doubling took more
than one year, and for patients with disease progression
(ie, patients who needed cytostatic treatment in any mo-
ment) (23 patients) versus those with stable disease during
the whole follow-up period.
METHODS
Serumsamplingandcytokinedetermination
The serum was obtained from each patient and stored at
−80◦C until measurements. All specimens were collected
with the consent of the donor. The cytokine serum concen-
trations were assayed by following speciﬁc enzyme-linked
immunoassay kits: VEGF, bFGF (R & D Systems Inc, Min-
neapolis, USA), sCD138 (Diaclone, Besanon, France), and
endostatin (Chemicon, UK). Standards and samples were as-
sayed as duplicates, and interassay variations were within the
range given by manufacturer. The project was performed in
accordance with the Helsinki Declaration with the approval
of the Local Ethics Committee.
Apoptosisassessment
Cells were obtained from 25 patients included to the
study at the same time as their sera. Mononuclear cells
were isolated from peripheral blood by standard centrifu-
gation over 1.077g/mL gradient (Gradisol L, Aqua Med-
ica, Poland). They were incubated over 24 hours in RPMI-
1640 medium supplemented with 10% heath-inactivated fe-
tal calf serum (Invitrogen, UK) and antibiotics at 37◦Ca n d
in 5% CO2 humidiﬁed atmosphere. Spontaneous apoptosis
of PBL was then cytoﬂuorometrically assessed after annexin
V/propidium iodide staining (Becton Dickinson PharMin-
gen, USA). Cells positively stained with annexin V only and
both with annexin V and propidium iodide were considered
as apoptotic.
Statisticalanalysis
Comparisons of values were performed with Mann-Whitney
test. Relationship between continuous variables was estab-
lished with Pearson’s correlation coeﬃcient. A cumulative
probability of survival without lymphocyte doubling (lym-
phocyte doubling-free survival, LDFS) and of survival with-
out progression, that is, before the appearance of an event
which justiﬁed the cytostatic treatment (progression-free
survival, PFS), was calculated according to Kaplan-Meyer
method.WeusedastheendpointsthedoublingofPBLcount
and the beginning of the treatment, respectively. Kaplan-
M e y e rc u r v e sw e r ec o m p a r e dw i t ht h eF-Cox test. A P<. 05
was considered as the level of statistical signiﬁcance.
RESULTS
The serum levels of VEGF, sCD138, and endostatin were
measurable in all healthy individuals and B-CLL patients.
We detected bFGF in sera of all B-CLL patients and in two
healthy subjects. Both bFGF and sCD138 levels were signiﬁ-
cantlyhigherinB-CLLpatientsthaninhealthycontrols(me-
dian value 18.4 pg/mL and 0.2 pg/mL for bFGF; 149.0 ng/mL
and 36.7 ng/mL for sCD138, resp, for B-CLL patients and for
control group) (Table 1). The serum levels of two other cy-
tokines were not signiﬁcantly diﬀerent between patients and
controls.Dariusz Wołowiec et al 3
Table 1: Comparison of serum levels (median, minimal, and maximal values) of VEGF, bFGF, syndecan 1, and endostatin in the healthy
control group and in 52 untreated B-CLL patients.
B-CLL patients
P Cytokine
Controls All LDT < 12 LDT ≥ 12 Stable Progressive
patients months months Disease Disease
N = 12 N = 52 N = 10 N = 42 N = 30 N = 22
1 2 3 4 5 6
1 3 5
versus versus versus
2 4 6
VEGF 456.2 326.5 247.43 351.9 326.5 322.3 NS NS NS
pg/mL (122.4–1029.6) (84.5–1547.8) (89.2–762.9) (84.5–1547.8) (84.5–833.4) (89.2–1547.8)
bFGF 0.2 18.4 11.64 20.9 16.4 20.9 .00001 NS .03
pg/mL (0.0–2.4) (0.0–529.5) (0.0–153.2) (0.0–529.5) (3.3–120.7) (0.0–529.5)
sCD138 36.7 149.0 54.2 178.8 187.9 65.1 .0002 .03 .03
ng/mL (17.4–135.8) (13.2–257.1) (13.2–201.2) (18.4–257.1) (27.3–257.1) (13.2–257.1)
Endostatin 5.9 8.12 8.38 8.12 7.56 9.34 NS NS NS
pg/mL (2.1–12.0) (2.3–20.6) (3.8–9.9) (2.3–20.6) (2.3–18.5) (3.8–20.6)
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Figure 1: Relationship between Syndecan-1 serum level and pe-
ripheral blond lymphocyte count in 52 untreated B-CLL patients
(the exponential curve is a supportive visualization).
Considering the relationship between cytokine levels and
biological variables, a negative correlation between PBL and
sCD138 was found (r =− 0.44, P = .001) (Figure 1).
According to that, the lymphocyte count was signiﬁcantly
lower in patients with sCD138 level above median value
(ie, 149.0ng/mL) than in patients with sCD138 level be-
low this value (20.8 ± 14.3G/Lversus 35.9 ± 16.9G/L,P<
.01). Similarly, the lymphocyte count was signiﬁcantly lower
in patients with endostatin level above median value (ie,
8.1ng/mL) as compared to patients with endostatin level be-
low median value (21.5 ± 15.9G/Lversus 29.0+1 4 .1G/L,P
.05). However, the correlation between these variables was
not statistically signiﬁcant (r =− 0.25, P = .1). We found
a positive correlation between VEGF level and platelet count
(r = 0.45, P = .003). We did not state other correlations
between cytokines tested and the following parameters: PBL,
hemoglobinlevel,plateletcount,2-microglobulinlevel,LDH
activity, CD38 expression, or bone marrow inﬁltration pat-
tern.
As shown in Table 1, in patients with progressive disease
bFGF level was signiﬁcantly higher, and sCD138 level was
signiﬁcantly lower as compared with stable disease. sCD138
level was signiﬁcantly lower in patients who doubled their
PBL within one year than in those with slower increase of the
lymphocyte number.
The analysis of LDFS and PFS curves after stratifying
the patients according to the median values of each cy-
tokine revealed that high sCD138 level was associated with
longer LDFS (Figure 2) and, on the limit of statistical signiﬁ-
cance,ahighendostatinlevelwasassociatedwithshorterPFS
(Figure 3). PFS was longer in patients with sCD138 serum
concentration above median value, and LDFS was shorter in
patients with endostatin concentration above median value
butdiﬀerencesbetweenrespectivecurveswerenotsigniﬁcant
(P = .14 for both pairs, not shown). The levels of the other
cytokines did not inﬂuence LDFS or PFS. For other biolog-
ical variables, only initial lymphocytosis below the median
value was associated with longer PFS.
Thespontaneous apoptosis oflymphocytesafter24-hour
culturerangedfrom3.75to42.9%(median:12.1).Therewas
no correlation between the percentage of apoptotic cells and
the serum concentration of sCD138 (r =− 0.17, P = .44) or
any other biological variables tested.4 Mediators of Inﬂammation
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Figure 2: Cumulative probability of lymphocyte doubling-free sur-
vival in 52 untreated CLL patients stratiﬁed on the basis of median
value of sCD138 (ie, 149.03ng/mL).
DISCUSSION
Syndecan-1 is a cytokine supposed to play a role in the dif-
ferentiation and survival of the B lymphocyte lineage cells.
It promotes myeloma cell apoptosis and exerts an inhibitory
eﬀect on their proliferation, and the elevated serum level
of its soluble form (sCD138) is an independent unfavorable
prognostic parameter [5–8]. The observation that CD138 is
detectable on B-CLL lymphocytes but not on other CD5-
positive lymphoma cells [9] raises the possibility that its ex-
pression may be related in some way to the pathogeny of
this disease. We attempted then to check if sCD138 is also
detectable in sera of B-CLL patients and if, like in multiple
myeloma, its serum level is related to biological features and
clinical outcome of this disorder. As the clinical stage is one
of the strongest prognostic factors we limited our study to
group of low and intermediate risk patients, that is, patients
with 0, I, or II stage according to Rai classiﬁcation. For prog-
nostic studies we considered two events: doubling of the PBL
number and progression of the disease. Because of the small
number of patients in whom the progression of Rai stage oc-
curred during the follow-up period, we could not use this
event as a criterion of progressive disease. We decided then
to consider as “progressive disease” group the cases with ne-
cessity of cytostatic treatment. Patients who did not receive
any treatment during the whole follow-up were then consid-
ered as stable disease group.
We stated that the serum concentration of sCD138 was
detectable in all B-CLL patients and was signiﬁcantly higher
than in age-matched healthy controls. An unexpected ﬁnd-
ing was the negative relationship between its serum level and
PBL. Moreover, the sCD138 level was signiﬁcantly lower in
patients with progressive disease when compared to the in-
dolent one, and in patients who doubled their PBL within
one year than in those with slower increase of the lympho-
cyte number.
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Figure 3: Cumulative probability of progression-free survival in 52
untreated CLL patients stratiﬁed on the basis of median value of
endostatin (ie, 8.12ng/mL).
In line with the latter ﬁnding, the cumulative proba-
bility of the doubling of PBL was lower in the group with
sCD138levelbelowmedianvalueascomparedtothepatients
with higher sCD138 level. This observation is diﬀerent from
what is currently known about the negative prognostic value
of sCD138 in multiple myeloma. The relationship demon-
strated by us is diﬃcult to explain, but it seems possible that
CD138 may promote the apoptosis and hamper the cell cy-
cle progression of B-CLL lymphocytes as it does in plasma
cells in in vitro model [6]. We assessed then a relationship
betweentheabilityofPBLtoundergospontaneousapoptosis
in vitro and serum sCD138 level of patients the lymphocytes
were collected from. We did not ﬁnd a correlation between
serumsCD138levelandthepercentageofapoptoticlympho-
cytesafter24-hourculture,butthelackofsuchcorrelationin
in vitro experimental conditions does not necessarily mean
that syndecan-1 does not inﬂuence the survival of leukemic
lymphocytes in vivo. Firstly, it is well known that the abil-
ity of B-CLL lymphocytes to undergo spontaneous apoptosis
in vitro does not correspond to the inhibition of their apop-
tosis in vivo. Secondly, a postulated proapoptotic action of
syndecan-1 in vivo or in vitro may require cooperation with
some other cytokines present in patients serum. The hypoth-
esis that serum sCD138 inﬂuences the survival of circulating
lymphocytes of CLL patients requires then conﬁrmation by
further studies. As other biological variables which we tested
were not correlated with the serum level of this cytokine, the
relationship with sCD138 level and lymphocytosis seems not
to be a “secondary eﬀect” of the inﬂuence of this cytokine
on some other parameter interrelated with the lymphocyte
count.
We also studied the levels of some cytokines known to be
involved in the angiogenesis in B-CLL. bFGF is a pleiotropic
cytokine which induces angiogenesis and is a ligand for
syndecan-1 [12–14]. It upregulates the expression of bcl-2
in B-CLL cell lines resulting in delaying apoptosis [15] whatDariusz Wołowiec et al 5
mayleadinvivototheenhancedaccumulationoflong-living
B-CLL lymphocytes and to the disease progression. Several
authors found that serum bFGF level was higher in patients
in advanced or progressive B-CLL than in patients with B-
CLL in early Rai stages or stable one [16–18]. In contrast,
Molica et al [19, 20] analyzed a group of Binet stage A pa-
tients and found a correlation of serum bFGF and Rai sub-
stages but not with PBL or disease progression. In our study,
carried out also on early stage-CLL (Rai 0, I, and II), bFGF
was higher in patients in progressive disease than in patients
with stable one. Our results seem then to conﬁrm some pre-
viously published observations that elevated concentration
ofthiscytokinemayheraldrapidprogressionofearlyB-CLL.
Several studies attempted to establish the importance of
serum VEGF, one of the key molecules involved in the an-
giogenesis, for the clinical behavior of B-CLL. Some au-
thors found a correlation between the serum concentration
of VEGF with a number of clinical and biological parame-
ters [21–23] as well as the increased risk of the disease pro-
gression in patients with elevated level of this cytokine. In
contrast, Molica et al [24], in his ﬁrst study published on
this topics performed on early stage B-CLL patients, did not
observe a relationship between VEGF level and PBL, bone
marrow histology, β2-microglobulin, LDH, or interleukin-
6 level. In our study we observed the previously described
positive correlation between serum VEGF and platelet count
[16], but not with PBL, hemoglobin level, β2-microglobulin
level, LDH activity, CD38 expression, or bone marrow in-
ﬁltration pattern. We also did not ﬁnd a prognostic value
of this cytokine for the disease progression or LDT, which
may be due to a relatively short follow-up period (median:
31 months) of our patients‘ cohort.
Finally we determined the serum level of endostatin, a
C-terminal fragment of collagen XVIII, an endogenous in-
hibitor of endothelial proliferation and tumor growth, hav-
ing a property to inhibit in vivo the angiogenesis and the
growth of both primary tumors and metastases [25]. Its
serum level was investigated in several solid tumors, and in
some of them (clear cell renal carcinoma and soft-tissue sar-
coma) it was higher than in healthy controls and associated
with increased risk of tumor recurrence [26–28]. Diﬀerently
from the ﬁndings of G´ ora-Tybor et al [29]p e r f o r m e do np a -
tients on both early and advanced stages of B-CLL, we did
not reveal a diﬀerence in the level of his cytokine between
patientswithstableandprogressivedisease.However,thecu-
mulative probability of progression-free survival was higher
(on the limit of statistical signiﬁcance) in patients with en-
dostatin level below the median value as compared with the
group with lower level of this cytokine. It is diﬃcult to ex-
plain why the increased level of this cytokine known as an-
tiproliferative and antiangiogenetic agent might be associ-
ated with worse prognosis, but negative prognostic value of
high endostatin level for was also found for overall survival
in acute myeloid leukemia/myelodysplastic syndrome [30],
andforthetumorrecurrenceofsoft-tissuesarcoma[26].The
prognostic value of serum endostatin level in B-CLL needs
then further studies on a larger cohort of patients and with
longer follow-up period.
Inconclusion,serumsCD138levelishigherinearlystage
B-CLLpatientsthaninhealthycontrols,correlatesnegatively
withperipheralbloodlymphocytecount,andishigherinpa-
tientswithmoreindolentdiseasecourse.Furthermore,bFGF
level is higher in patients with progressive disease. The prog-
nosticsigniﬁcanceofVEGFfortheriskofdiseaseprogression
requiresfurtherstudies.Finally,elevatedendostatinlevel,de-
spite its properties as an antiangiogenic and antiproliferative
agent as shown on animal models, may have negative prog-
nostic signiﬁcance as to the probability of disease progres-
sion.
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